Enzymatrix International Co., Ltd. – Trademark Portfolio

Entity Type: 99

Enzymatrix International Co., Ltd. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. Currently, 1 trademark is registered. Notable registered marks include BOTAGOVY. The owner is based in Mahé,.

Vistra Corporate Services Centre, Suite

23, 1st Floor, Eden Plaza, Eden Island,

Mahé, 999126 , SC

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

OZEMQUIK
OZEMQUIK
Abandoned 2023
BOTAGOVY
BOTAGOVY
Registered 2023
HYPUSYN
HYPUSYN
Abandoned 2021

Trademark Classifications

Enzymatrix International Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Enzymatrix International Co., Ltd. have?

Enzymatrix International Co., Ltd. has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 abandoned.

What trademark classes does Enzymatrix International Co., Ltd. file in?

Enzymatrix International Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Enzymatrix International Co., Ltd.'s most well-known trademarks?

Enzymatrix International Co., Ltd.'s registered trademark portfolio includes well-known marks such as BOTAGOVY. These are among 1 currently registered trademark in the portfolio.

What is Enzymatrix International Co., Ltd.'s trademark registration success rate?

Enzymatrix International Co., Ltd. has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.